PHARNEXT SCA 
Details are as follow:
Date & Time | Title |
September 14 -15, 2017 All day | Poster #90: "A multicenter, double-blind, placebo-controlled, pivotal Phase III study (PLEOCMT) of a fixed combination of baclofen, naltrexone and sorbitol (PXT3003), for the treatment of CMT1A" S. Attarian et al. |
The abstract is available online at : http://www.aanem.org/Meetings/Annual-Meeting/Abstracts
About PXT3003PXT3003, Pharnext's lead PLEODRUG™ in development for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), is a novel, synergistic, low-dose combination of baclofen, naltrexone, and D-sorbitol formulated as an oral solution given twice-daily. PXT3003 has multiple main mechanisms of action: a synergistic inhibition of PMP22 gene overexpression associated with myelination improvement, direct nerve protection and additional positive effects on other cellular types: muscle cells, neuromuscular junctions and immune cells. PXT3003 obtained positive results in a Phase II clinical trial in 80 adult patients with CMT1A. In 2014, the EMA and FDA granted orphan drug designation to PXT3003 for the treatment of CMT1A in adults. An international pivotal Phase III trial (PLEO-CMT) in over 300 adult patients with CMT1A is now underway at 30 sites across Europe, the U.S. and Canada.
About PharnextPharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of
PHARNEXT | CREATING NEW SOLUTIONSrepositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com
CONTACTSPharnext Xavier Paoli Chief Commercial Officer contact@pharnext.com +33 (0)1 41 09 22 30 | Pharnext René Goedkoop Chief Medical Officer contact@pharnext.com +33 (0)1 41 09 22 30 | |
Investor Relations (Europe) MC Services AG Anne Hennecke anne.hennecke@mc-services.eu +49 211 529252 22 | Investor Relations (U.S.) Stern Investor Relations, Inc. Matthew Shinseki matthew@sternir.com +1 212-361-1200 | Financial Communication (France) New CAP Emmanuel Huynh pharnext@newcap.eu +33 (0)1 44 71 20 40 |
Media Relations (Europe) ALIZE RP Caroline Carmagnol Margaux Pronost pharnext@alizerp.com +33 (0)1 44 54 36 64 | Media Relations (U.S.) Russo Partners Tony Russo Scott Santiamo tony.russo@russopartnersllc.comscott.santiamo@russopartnersllc.com +1 212-845-4251 +1 718-344-5843 |
Pharnext SA published this content on 07 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 07 September 2017 16:12:03 UTC.
Original documenthttps://www.pharnext.com/images/PDF/press_releases/2017.09.07_AANEM_EN.pdf
Public permalinkhttp://www.publicnow.com/view/58DBADB18B06F2570A48F98D5139A19B84F7BE4E
